An amlodipine lawsuit today almost always means one of two things: a claim tied to cancer-causing contamination found in amlodipine-valsartan combination pills, or an individual injury or malpractice claim built on amlodipine’s known side effects. There is no mass tort aimed at amlodipine itself. The drug, sold by Pfizer as Norvasc and widely available as a generic, has been at the center of major patent fights and a sprawling contamination multidistrict litigation, but those are different animals, and which one applies to you depends entirely on what you took and what happened next.
The Valsartan-Amlodipine NDMA Litigation
The largest active litigation touching amlodipine is not really about amlodipine. It concerns valsartan, a blood pressure drug frequently sold in combination with amlodipine, that was found to be contaminated with nitrosamine impurities classified as probable human carcinogens. Starting in mid-2018, the FDA issued alerts about N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) in active pharmaceutical ingredient supplied by manufacturers including Zhejiang Huahai Pharmaceuticals in China and Mylan India.
Combination products containing amlodipine were pulled from the market alongside the standalone valsartan pills. Torrent Pharmaceuticals Limited issued a voluntary nationwide recall of all lots of its valsartan/amlodipine/HCTZ, valsartan/amlodipine, and valsartan tablets in August 2018 after NDMA was detected in the Zhejiang Huahai API.1FDA. Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall In November 2018, Teva Pharmaceuticals USA recalled all lots of its amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide tablets after NDEA was found above specification limits in API from Mylan India.2FDA. Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Aurobindo Pharma and other manufacturers issued further recalls through 2019.3FDA. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls
Patients who took contaminated products and later developed cancer filed suit, and those cases were consolidated as In Re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, MDL No. 2875, in the U.S. District Court for the District of New Jersey.4U.S. District Court, District of New Jersey. Valsartan MDL 2875 Chief U.S. District Judge Renée Marie Bumb presides. Amlodipine/valsartan combination products, including brand names Exforge and Exforge HCT, sit explicitly within the scope of the MDL.5Robert King Law Firm. Valsartan Lawsuit
Where the MDL Stands
The litigation is active but has not produced verdicts or a global settlement. As of March 2026, 1,418 lawsuits were pending in the MDL.6Lawsuit Tracker. Valsartan Lawsuit A Daubert hearing on the admissibility of expert testimony linking NDMA exposure to cancer was held on October 3, 2025.5Robert King Law Firm. Valsartan Lawsuit The court ordered a second round of test cases, and a June 2025 scheduling order set an October 8, 2025 deadline for expert and summary judgment motions in four Wave 2 bellwethers, with trial dates still to be set.7Nigh Goldenberg Raso & Vaughn. Valsartan Lawsuit – Second Amended Wave 2 Bellwether Schedule A separate class-action settlement motion was filed in October 2025 covering irbesartan claims; Aurobindo continues to deny liability.
In December 2023, the court certified three plaintiff classes in the MDL: Consumer Economic Loss, Medical Monitoring, and Third Party Payor.8You Have a Lawyer. Valsartan In April 2025, the court approved a process requiring each plaintiff to prove they actually used a recalled version of the drug made by the specific defendant they are suing, which is expected to narrow the pool of viable claims.9Levin Law. Valsartan Lawsuit
Who Can File
The threshold questions are straightforward. Did you take a recalled amlodipine/valsartan or valsartan-containing combination product? Can you tie the pills you took to a specific manufacturer covered by the recalls, given the April 2025 proof-of-use requirement? Did you develop a cancer during or after a plausible latency period? Straight amlodipine, taken alone and never combined with valsartan, is not part of MDL 2875.
Injury Claims Based on Amlodipine’s Side Effects
Amlodipine on its own has no consolidated litigation, but the drug carries documented risks that can support individual claims where the facts support them. Peripheral edema, swelling in the legs and feet, occurs in roughly 10.8% of patients on the 10 mg dose.10National Library of Medicine. Amlodipine The FDA-approved Norvasc label warns of worsening heart failure, pulmonary edema, and worsening angina or heart attack in patients with severe coronary artery disease, particularly when starting the drug or increasing the dose. The label also flags careful dosing in patients with liver disease, because the drug is extensively metabolized by the liver and impairment can push blood levels dangerously high. Amlodipine does not carry an FDA black box warning.11FDA. Norvasc (Amlodipine Besylate) Prescribing Information
Individual cases against a manufacturer typically proceed on one of three theories. A manufacturing defect claim alleges contamination or incorrect dosing in a specific batch. A design defect claim argues the drug’s risks outweigh its benefits for a particular patient population. A failure-to-warn claim asserts that the manufacturer did not adequately communicate known risks to prescribing physicians. A malpractice claim against a prescriber can also arise, for instance where amlodipine was given despite a known contraindication like severe aortic stenosis or unstable angina. These are assessed one at a time on their own facts, not as part of any consolidated proceeding.
Patent Litigation Involving Norvasc: What It Was and Wasn’t
Searches for amlodipine lawsuits sometimes turn up the older Norvasc patent cases. Those were commercial disputes between Pfizer and generic manufacturers, not injury claims. Pfizer’s U.S. Patent No. 4,879,303 covered the besylate salt form of amlodipine, and Pfizer sued companies including Apotex and Synthon after they filed generic applications with Paragraph IV certifications. A district court initially upheld the patent against Apotex, enjoining the company from selling generic amlodipine until September 25, 2007.12FindLaw. Pfizer Inc. v. Apotex, Inc.
On March 22, 2007, the U.S. Court of Appeals for the Federal Circuit reversed, holding claims 1 through 3 of the ‘303 patent invalid as obvious.12FindLaw. Pfizer Inc. v. Apotex, Inc. Mylan Laboratories, which had filed the first generic application, launched the next day and then fought the FDA in the District of Columbia over whether its 180-day generic exclusivity survived. On June 29, 2007, U.S. District Judge Ricardo M. Urbina denied Mylan’s request for a restraining order, finding the FDA’s contrary interpretation reasonable and rejecting what he called a “distortion of the principles of the Hatch-Waxman Act.”13GovInfo. Mylan Labs., Inc. v. Leavitt, Case No. 07-579 None of this gives a patient a cause of action. It’s why generic amlodipine is cheap and everywhere, not a basis for personal injury recovery.
What to Do Next
Pull your pharmacy records. If any of your prescriptions were for amlodipine-valsartan combinations, or for Exforge or Exforge HCT, check the manufacturer and lot numbers against the FDA’s recall lists and consult a lawyer handling MDL 2875 claims, particularly given the proof-of-use requirement the court imposed in April 2025. If your concern is a side effect from amlodipine itself, such as a cardiac event or a serious drug interaction, that is an individual case to evaluate with a product liability or medical malpractice attorney on its own facts. Statutes of limitations vary by state and by the date you knew or should have known of the injury, so timing matters either way.